232 related articles for article (PubMed ID: 15700051)
1. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.
Hall WH; Jani AB; Ryu JK; Narayan S; Vijayakumar S
Prostate Cancer Prostatic Dis; 2005; 8(1):22-30. PubMed ID: 15700051
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer.
Walz J; Gallina A; Hutterer G; Perrotte P; Shariat SF; Graefen M; McCormack M; Bénard F; Valiquette L; Saad F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):88-94. PubMed ID: 17446004
[TBL] [Abstract][Full Text] [Related]
3. Prognostic features in men who died of prostate cancer.
Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
[TBL] [Abstract][Full Text] [Related]
4. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
5. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.
Kastner C; Armitage J; Kimble A; Rawal J; Carter PG; Venn S
Prostate Cancer Prostatic Dis; 2006; 9(3):270-4. PubMed ID: 16770340
[TBL] [Abstract][Full Text] [Related]
6. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
[TBL] [Abstract][Full Text] [Related]
7. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study.
Lund L; Borre M; Jacobsen J; Sørensen HT; Nørgaard M
Urology; 2008 Dec; 72(6):1258-62. PubMed ID: 18342917
[TBL] [Abstract][Full Text] [Related]
8. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
9. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.
Walz J; Gallina A; Perrotte P; Jeldres C; Trinh QD; Hutterer GC; Traumann M; Ramirez A; Shariat SF; McCormack M; Perreault JP; Bénard F; Valiquette L; Saad F; Karakiewicz PI
BJU Int; 2007 Dec; 100(6):1254-8. PubMed ID: 17979925
[TBL] [Abstract][Full Text] [Related]
10. Relative importance of PSA in prostate cancer treatment.
Unger HA; Kane RD; Fox KM; Gandhi S; Alzola C; Lamerato L; Newling D; Kumar S
Urol Oncol; 2005; 23(4):238-45. PubMed ID: 16018938
[TBL] [Abstract][Full Text] [Related]
11. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
12. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
13. Is there an optimal comorbidity index for prostate cancer?
Alibhai SM; Leach M; Tomlinson GA; Krahn MD; Fleshner NE; Naglie G
Cancer; 2008 Mar; 112(5):1043-50. PubMed ID: 18286512
[TBL] [Abstract][Full Text] [Related]
14. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
15. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
Dahm P; Yeung LL; Chang SS; Cookson MS
J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
[TBL] [Abstract][Full Text] [Related]
16. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer.
Birim O; Kappetein AP; Bogers AJ
Eur J Cardiothorac Surg; 2005 Nov; 28(5):759-62. PubMed ID: 16157485
[TBL] [Abstract][Full Text] [Related]
17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
18. Management of localized prostate cancer in senior adults: the crucial role of comorbidity.
Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 2():16-22. PubMed ID: 18307688
[TBL] [Abstract][Full Text] [Related]
19. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer in the elderly.
Heinzer H; Steuber T
Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
